Rules on off-label marketing at stake in appeal of conviction

12/5/2012 | Wall Street Journal, The

A federal appeals court in California will consider today if former InterMune CEO W. Scott Harkonen committed fraud in promoting the lung-disease treatment Actimmune. Harkonen and his attorneys are appealing a wire fraud conviction from 2009 involving the alleged survival benefits of the drug. Conveying a scientific view should be protected by First Amendment free-speech rights, the attorneys said.

View Full Article in:

Wall Street Journal, The

Published in Brief: